Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Kim

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
Frontiers in Oncology|October 31, 2022
Prognostic role of HPV integration status and molecular profile in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trialAlice Debernardi, Aurélia Meurisse, Jean-Luc Prétet, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|December 11, 2019
RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter studyOlivier Lucidarme, Mathilde Wagner, Paul Gillard, et al.
Cancer Research Communications|January 14, 2025
Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT TrialsAngélique Vienot, Dewi Vernerey, Adeline Bouard, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 14, 2015
Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinomaMarine Jary, Dewi Vernerey, Thierry Lecomte, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2022
Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II studyBenoit Rousseau, Arezki K Boukerma, Julie Henriques, et al.
International Journal of Cancer|July 30, 2016
Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological scoreMarine Jary, Thierry Lecomte, Olivier Bouché, et al.
Molecular Cancer|July 29, 2023
Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genesLorraine Dalens, Julie Niogret, Corentin Richard, et al.
Mabs|March 30, 2017
A new anti-mesothelin antibody targets selectively the membrane-associated formKamal Asgarov, Jeremy Balland, Charline Tirole, et al.
International Journal of Cancer|March 31, 2020
Molecular description of ANGPT2 associated colorectal carcinomaMarine Jary, Reyhan Hasanova, Angélique Vienot, et al.
British Journal of Cancer|October 8, 2021
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin gradeRobin Kate Kelley, Rebecca Miksad, Irfan Cicin, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Frontiers in Oncology|October 31, 2022
Prognostic role of HPV integration status and molecular profile in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trialAlice Debernardi, Aurélia Meurisse, Jean-Luc Prétet, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|December 11, 2019
RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter studyOlivier Lucidarme, Mathilde Wagner, Paul Gillard, et al.
Cancer Research Communications|January 14, 2025
Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT TrialsAngélique Vienot, Dewi Vernerey, Adeline Bouard, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 14, 2015
Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinomaMarine Jary, Dewi Vernerey, Thierry Lecomte, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2022
Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II studyBenoit Rousseau, Arezki K Boukerma, Julie Henriques, et al.
International Journal of Cancer|July 30, 2016
Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological scoreMarine Jary, Thierry Lecomte, Olivier Bouché, et al.
Molecular Cancer|July 29, 2023
Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genesLorraine Dalens, Julie Niogret, Corentin Richard, et al.
Mabs|March 30, 2017
A new anti-mesothelin antibody targets selectively the membrane-associated formKamal Asgarov, Jeremy Balland, Charline Tirole, et al.
International Journal of Cancer|March 31, 2020
Molecular description of ANGPT2 associated colorectal carcinomaMarine Jary, Reyhan Hasanova, Angélique Vienot, et al.
British Journal of Cancer|October 8, 2021
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin gradeRobin Kate Kelley, Rebecca Miksad, Irfan Cicin, et al.
Pageof 7